146940-41-2

Upstream product

• 536-74-3 phenylacetylene 
• 1458-02-2 Methyl 3,5-diamino-6-iodopyrazine-2-carboxylate 
• 1458-19-1 methyl 3,5-diamino-2-pyrazinecarboxylate 
• 1458-01-1 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid methyl ester 
• 13146-23-1 copper(I) phenylacetylenide 

Downstream Products

• 1345839-41-9 C₁₄H₁₃N₇O*ClH 
• 146940-42-3 6-Phenylethinylamiloride 

Relevant academic research and scientific papers

Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)

A known side-activity of the oral potassium-sparing diuretic drug amiloride is inhibition of the enzyme urokinase-type plasminogen activator (uPA, K i = 7 μM), a promising anticancer target. Several studies have demonstrated significant antitum

Preparation and diuretic properties of novel amiloride analogues

Fifteen novel amiloride analogues were synthesized and their diuretic properties compared to amiloride and triamterene in white wistar rats. Whereas none of the 6-substituted derivatives exhibited significant natriuretic and antikaliuretic effects, five of the compounds modified in the 2-position were found equal or better than standards. The results are discussed with respect to chemical structure and physicochemical properties.